Fei Weiqiang, Chen Li, Chen Jiaxin, Shi Qinglan, Zhang Lumin, Liu Shuiping, Li Lingfei, Zheng Lili, Hu Xiaotong
Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
Oncotarget. 2017 Sep 21;8(54):92254-92264. doi: 10.18632/oncotarget.21173. eCollection 2017 Nov 3.
The potential role of serum RBP4 and THBS2 as biomarker in colorectal cancer (CRC) diagnosis has never been studied. We investigated in large sample using quantitative ELISA method to explore whether serum RBP4 and THBS2 can act as biomarkers for CRC diagnosis. The concentration of RBP4 and THBS2 was measured in 402 CRC patients' serum samples and 218 normal controls' serum samples. The results showed that the average RBP4 and THBS2 concentrations in normal controls were significantly higher than in CRC patients (36.5±11.4μg/mL vs 21.8±8.7μg/mL and 20.5±6.1ng/mL vs 14.5±7.3ng/mL, respectively), both p<0.001. RBP4 distinguished CRC patients from normal individuals with the area under the receiver operating characteristic curve (AUC) performing at 0.852, with sensitivity of 74.9% and specificity of 81.7%. While THBS2 distinguished CRC patients performing AUC at 0.794, with sensitivity of 64.9% and specificity of 87.1%. The ability of RBP4 and THBS2 serum concentration distinguishing CRC from normal controls showed better than that of serum CEA (AUC=0.818) or CA19-9 (AUC=0.650) concentration. This is the first study to report RBP4 and THBS2 as diagnosis serum biomarkers for CRC, which might be a good supplement for CEA or CA19-9 for clinical diagnosis.
血清视黄醇结合蛋白4（RBP4）和血小板反应蛋白2（THBS2）作为生物标志物在结直肠癌（CRC）诊断中的潜在作用从未被研究过。我们采用定量酶联免疫吸附测定（ELISA）方法对大样本进行研究，以探索血清RBP4和THBS2是否可作为CRC诊断的生物标志物。测定了402例CRC患者血清样本和218例正常对照血清样本中RBP4和THBS2的浓度。结果显示，正常对照中RBP4和THBS2的平均浓度显著高于CRC患者（分别为36.5±11.4μg/mL对21.8±8.7μg/mL和20.5±6.1ng/mL对14.5±7.3ng/mL），两者p均<0.001。RBP4区分CRC患者和正常个体的受试者工作特征曲线下面积（AUC）为0.852，敏感性为74.9%，特异性为81.7%。而THBS2区分CRC患者的AUC为0.794，敏感性为64.9%，特异性为87.1%。RBP4和THBS2血清浓度区分CRC与正常对照的能力优于血清癌胚抗原（CEA）（AUC=0.818）或糖类抗原19-9（CA19-9）（AUC=0.650）浓度。这是首次报道RBP4和THBS2作为CRC诊断血清生物标志物的研究，它们可能是CEA或CA19-9临床诊断的良好补充。
